Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
6,140
Employees6,140
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
6,140
Employees6,140

NTRA Key Statistics

Market cap
27.67B
Market cap27.67B
Price-Earnings ratio
-91.08
Price-Earnings ratio-91.08
Dividend yield
Dividend yield
Average volume
1.10M
Average volume1.10M
High today
$208.04
High today$208.04
Low today
$196.22
Low today$196.22
Open price
$200.17
Open price$200.17
Volume
1.48M
Volume1.48M
52 Week high
$256.36
52 Week high$256.36
52 Week low
$125.38
52 Week low$125.38

Stock Snapshot

As of today, Natera(NTRA) shares are valued at $200.17. The company's market cap stands at 27.67B, with a P/E ratio of -91.08.

On 2026-03-02, Natera(NTRA) stock moved within a range of $196.22 to $208.04. With shares now at $200.17, the stock is trading +2.0% above its intraday low and -3.8% below the session's peak.

Trading volume for Natera(NTRA) stock has reached 1.48M, versus its average volume of 1.1M.

The stock's 52-week range extends from a low of $125.38 to a high of $256.36.

The stock's 52-week range extends from a low of $125.38 to a high of $256.36.

NTRA News

TipRanks 3d
Natera: Sustained Outperformance, Conservative 2026 Guidance, and Innovation-Driven Upside Support Buy Rating and $285 Target

Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Buy rating on Natera, retaining the price target of $285.00. Claim 50% Off TipRanks Premium Unlock hed...

TipRanks 3d
Natera to present new data in geniturinary malignancies at ASCO GU

Natera (NTRA) will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium, taking place Feb...

TipRanks 3d
Natera price target raised to $260 from $250 at Evercore ISI

Evercore ISI raised the firm’s price target on Natera (NTRA) to $260 from $250 and keeps an Outperform rating on the shares. Published first on TheFly – the ul...

Analyst ratings

87%

of 23 ratings
Buy
87%
Hold
13%
Sell
0%

More NTRA News

Simply Wall St 4d
Is It Time To Reassess Natera After Strong Multi Year Share Price Gains

If you are wondering whether Natera's current share price reflects its real value, you are not alone. This article will help you frame that question clearly. N...

Is It Time To Reassess Natera After Strong Multi Year Share Price Gains
TipRanks 4d
Natera: Underpenetrated Growth, Emerging Catalysts, and a Clear Path to Cash Flow Support a Buy Rating

Daniel Brennan, an analyst from TD Cowen, maintained the Buy rating on Natera. The associated price target remains the same with $280.00. Daniel Brennan has gi...

Nasdaq 4d
Natera Q4 2025 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Natera Q4 2025 Earnings Call Transcript
TipRanks 4d
Natera reports FY25 EPS ($1.52), consensus ($2.42)

Reports Q4 revenue $665.M, consensus $600.7M. Reports Q4: Product revenues grew 39.8% over the same period. Generated a gross margin1 of 66.9% in the fourth qua...

TipRanks 6d
Natera says Phase 2 SINERGY trial met primary endpoint

Natera (NTRA) announced results from the SINERGY trial, a Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma. Data was recently pres...

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.